

Application No. 09/724,311
 Amendment dated September 21, 2004
 Response to Office Action mailed April 26, 2004

Amendments to the Specification:

Please replace paragraph beginning at page 6, line 8 with the following replacement paragraph:

Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (*see generally* Ausubel *et al.*, *supra*). One example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). Typically, default program parameters can be used to perform the sequence comparison, although customized parameters can also be used. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89, 10915 (1989))

Please replace the paragraph beginning on page 5, line 20 of the specification with the following replacement paragraphs.

Figs. 15A-E: A β levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A β level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.

Fig. 15A: The values for mice for the PBS-treated control group and the untreated control group.

Fig. 15B: The values for mice in the AN1528/alum and AN1528/MPL-treatment groups.

Application No. 09/724,315
Amendment dated September 21, 2004
Response to Office Action mailed April 26, 2004

Fig. 15C: The values for mice in the AN1528/OS21 and AN1792/Freund's adjuvant treatment groups.

Fig. 15D: The values for mice in the AN1792/Thimerosal and AN1792/alum treatment groups.

Fig. 15E: The values for mice in the AN1792/MPL and AN1792/OS21 treatment groups.

Please replace the paragraph beginning on page 70, line 13 of the specification with the following replacement paragraphs.

Sixty male and female, heterozygous PDAPP transgenic mice, 8.5 to 10.5 months of age were obtained from Charles River Laboratory. The mice were sorted into six groups to be treated with various antibodies directed to A β . Animals were distributed to match the gender, age, parentage and source of the animals within the groups as closely as possible. As shown in Table 10, the antibodies included four murine A β -specific monoclonal antibodies, 2H3 (directed to A β residues 1-12), 10D5 (directed to A β residues 1-16), 266 (directed to A β residues 13-28 and binds to monomeric but not to aggregated AN1792), 21F12 (directed to A β residues 33-42). The cell line designated hybridoma resulting from fusion of SP/20 with A/J mouse spleen: 266,2 producing the antibody 266 has the ATCC accession number PTA-6123, having been deposited on July 20, 2004. A fifth group was treated with an A β -specific polyclonal antibody fraction (raised by immunization with aggregated AN1792). The negative control group received the diluent, PBS, alone without antibody.